Ischemic Heart Disease Clinical Trial
Official title:
Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study
To study the role of Vigileo monitor using the FloTrac sensor to measure cardiac output using the pulse contour analysis as well as central venous oxygen saturation monitoring as a guide for tissue perfusion. The accuracy of the Vigileo monitoring was compared with the conventional thermodilution method for measuring cardiac output using the pulmonary artery catheter and mixed venous oxygen saturation for assessing global tissue perfusion.
Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac
Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A
Prospective Study
OBJECTIVE: To study the role of Vigileo monitor using the FloTrac sensor to measure cardiac
output using the pulse contour analysis as well as central venous oxygen saturation
monitoring as a guide for tissue perfusion. The accuracy of the Vigileo monitoring was
compared with the conventional thermodilution method for measuring cardiac output using the
pulmonary artery catheter and mixed venous oxygen saturation for assessing global tissue
perfusion.
DESIGN: A prospective clinical study conducted at the cardiothoracic operating theatre and
the cardiothoracic intensive care unit of Sultanah Aminah Hospital Johor Bahru.
PARTICIPANTS: 60 patients from the time of induction of anaesthesia to post operative Day 1
in the cardiothoracic intensive care unit.
INTERVENTIONS: Simultaneous cardiac output measurements using the Vigileo FloTrac sensor and
thermodilution method using the PAC will be obtained at the following intervals: Post
Induction( T0), Pre CPB( T1), Post CPB( T2), 1 hour post ICU admission( T3), 4 hours post
ICU admission( T4), 1 hour post extubation( T5) and post operative Day 1 at 0700(T6).
Central venous oxygen saturation measurements and mixed venous oxygen saturation using the
PAC was also obtained at similar interval times as above. Low central venous oxygen
saturation is defined as less than 70% while low mixed venous oxygen saturation was fixed as
less than 65% for appropriate interventions to be instituted to improve oxygen delivery.
Arterial blood gases will also be done at the scheduled interval to validate whether the
presence of metabolic acidosis can be used to correlate with central or mixed venous oxygen
saturation measurements.
MEASUREMENTS AND RESULTS: Demographic data that was recorded include age, sex, body weight,
height, and body mass index, type of surgery, ejection fraction, time on cardiopulmonary
bypass, Euroscore, haemoglobin and haematocrit levels.
At the scheduled interval, cardiac output measurements using the thermodilution method as
well as the pulse contour analysis method using the Vigileo FloTrac system will be done.
Mixed venous oxygen (SvO2) will be sampled simultaneously with the central venous oxygen
saturation (ScvO2 ).
Demographic data will be summarized as mean ± SD where appropriate. Bland -Altman plot will
be done to compare both methods for obtaining the cardiac output measurements. Linear
regression analysis, Bland-Altman plot and Pearson test will be used to evaluate the
correlation between SvO2 and ScvO2. A p-value of < 0.05 will be considered as significant.
EXCLUSION CRITERIA: Patients will be excluded if they are on Intra Aortic Balloon Pump
(IABP), requiring emergency chest reopening, significant arrhythmia which causes an
irregular arterial waveform and tricuspid regurgitation as ruled out during the pre
operative echocardiogram.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |